A股異動 | 藍豐生化漲停 第三季度純利同比增長108.64%
格隆匯10月24日丨藍豐生化(002513.SZ)今日漲停,封單逾5萬手。現報6.29元,暫成交6234萬元,最新總市值21.4億元。藍豐生化日前披露三季報稱,公司今年前三季度實現營業收入11.85億元,同比增長3.22%;歸屬於上市公司股東的淨利潤2756.51萬元,同比增長178.25%;基本每股收益0.08元。其中,第三季度實現歸屬於上市公司股東的淨利潤570.03萬元,同比增長108.64%。此外,公司預計2019年度歸屬於上市公司股東的淨利潤為2800至3800萬元。據悉,藍豐生化主要業務為農化業務、醫藥業務,曾因淨利潤連續虧損被深交所實行退市風險警示,2016年終於盈利藉此摘帽,2018年再次陷入虧損,淨利潤虧損逾8億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.